Evidence map›Paper›PMID 32753497›Full record

ArticlemBio2020

Phage-Antibiotic Synergy Is Driven by a Unique Combination of Antibacterial Mechanism of Action and Stoichiometry.

Carmen Gu Liu, Sabrina I Green, Lorna Min, Justin R Clark, Keiko C Salazar, Austen L Terwilliger, Heidi B Kaplan, Barbara W Trautner, Robert F Ramig, Anthony W Maresso

Open access · goldAbstract read
In one paragraph

Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 256 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
256citing papers in PubMed, 1 pooled it
25.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

256 citing papers in PubMed, 1 synthesis or guideline pooled it, 346 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Vancomycin and phage COP-80B combination therapy for Staphylococcus epidermidis periprosthetic joint infections: a preclinical mouse study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

196 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Carmen Gu LiuTailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-4491-3173
Sabrina I GreenTailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Lorna MinSchool of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Justin R ClarkTailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Keiko C SalazarTailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Austen L TerwilligerTailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Heidi B KaplanDepartment of Microbiology and Molecular Genetics, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Barbara W TrautnerTailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Robert F RamigTailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Anthony W MaressoTailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR), Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA Anthony.maresso@bcm.edu.
Baylor College of Medicine · USMichael E. DeBakey VA Medical Center · USThe University of Texas Health Science Center at Houston · US

Funding

Novel Platforms for Human Intestinal Enteroids: Matrix, Mechanics, and TopographyU19AI116497 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI ESTES, MARY KOLB · 2015 to 2025
$13.2M
Bacteriophage to treat multidrug‐resistant UTI in Persons with Spinal Cord InjuryI01RX002595 · VA · MICHAEL E DEBAKEY VA MEDICAL CENTER · PI TRAUTNER, BARBARA WELLS · 2019 to 2023
–
NIAID NIH HHS U19 AI116497RRD VA I01 RX002595
6 · The paper itself

Abstract

The continued rise in antibiotic resistance is precipitating a medical crisis. Bacteriophage (phage) has been hailed as one possible therapeutic option to augment the efficacy of antibiotics. However, only a few studies have addressed the synergistic relationship between phage and antibiotics. Here, we report a comprehensive analysis of phage-antibiotic interaction that evaluates synergism, additivism, and antagonism for all classes of antibiotics across clinically achievable stoichiometries. We combined an optically based real-time microtiter plate readout with a matrix-like heat map of treatment potencies to measure phage and antibiotic synergy (PAS), a process we term synography. Phage-antibiotic synography was performed against a pandemic drug-resistant clonal group of extraintestinal pathogenic

Indexed as

Anti-Bacterial AgentsBacteriophagesDrug AntagonismDrug Resistance, Multiple, BacterialDrug SynergismEscherichia coliHumansMicrobial Sensitivity TestsPhage TherapyAnti-Bacterial Agentsadjuvantantibioticbacteriophageclinical isolatecombinatorial treatmentEscherichia coliphagephage therapysynergysynogramsynography

Identifiers

PMID32753497
PMCPMC7407087
OpenAlexW3047234466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.